Pharma Industries Bets $10 Million on Paraguay’s Medicinal Cannabis Ambitions
Paraguay’s pharmaceutical sector is entering a new phase as Pharma Industries, a company founded in 2007 by Dr. Oscar Vicente Scavone and now led by President and CEO Shawn Vahdat, officially launches its medicinal cannabis line, TodoCANN. The move follows a multi-year investment of over US$10 million, channelled into infrastructure, research, and local talent development since 2019.
The TodoCANN range includes sublingual drops and teas containing CBD and THC, produced entirely in Paraguay under what the company describes as international pharmaceutical standards. Pharma Industries emphasises full traceability and quality control, having built a vertically integrated operation that spans from genetics and cultivation through extraction and final formulation—all in controlled indoor environments aligned with Good Manufacturing Practices (GMP).
Vahdat told Forbes Paraguay that the country now has “a consolidated regulatory framework, greater scientific knowledge, and growing demand for evidence-based therapeutic alternatives,” positioning it to become a regional leader in medicinal cannabis. The launch is not limited to the domestic market; the company plans to expand its product portfolio and enter foreign markets, while forging alliances with universities and research centres to bolster clinical evidence and medical education.
Where Pharma Industries’ Vertical Integration Leaves Competitors
Pharma Industries’ Strategic Moat
The company’s key differentiator is its vertically integrated, indoor production model. By controlling every step—from seed genetics to final packaged medicine—it can guarantee pharmaceutical-grade purity and stability, a significant barrier to entry for competitors relying on third-party supply chains or outdoor cultivation susceptible to environmental variability. This GMP-aligned approach aligns Pharma with the stringent standards required by export markets, particularly in Europe and other regulated jurisdictions.
Paraguay’s Regulatory Window
Pharma Industries is capitalising on what it describes as a more mature local regulatory environment for medicinal cannabis. While Paraguay has long been associated with industrial cannabis, the shift toward pharmaceutical-grade production with clear traceability opens a high-value niche. The company’s bet is that being an early mover with a fully compliant, export-ready facility will allow it to capture first-mover advantages as neighbouring markets like Brazil and Argentina gradually expand patient access to cannabis-based medicines.
The Real Competition Isn’t Local
Direct competition from other Paraguayan pharma companies is currently limited in this specific segment, but the strategic threat comes from larger regional players—Canadian, Colombian, and Uruguayan firms that have already scaled regulated medicinal cannabis production. Pharma Industries’ US$10 million investment is modest by global standards, so success will hinge on executing its export strategy rapidly and securing partnerships with healthcare providers and distributors abroad before these bigger rivals dominate Latin American distribution channels.
What Pharma’s Move Means for the Industry and Investors
- For Pharma Industries: The immediate priority is securing export certifications that recognise its GMP-compliant indoor facility. Any delays in mutual recognition agreements with target markets (e.g., Brazil’s ANVISA or the EU’s EMA) would cap the return on its vertical integration investment.
- For investors and rivals: Watch for clinical trial registrations or university partnerships announced by Pharma—these will signal whether the company can generate the local scientific evidence it says is critical to building physician confidence and differentiating its products from imported alternatives.
- For regional healthcare systems: The arrival of a domestically produced, pharmaceutical-grade medicinal cannabis line could pressure regulators in neighbouring countries to accelerate their own guidelines, creating a wider market but also inviting more competition into Paraguay’s early-mover space.
Risk & Opportunity Assessment
| Commercial Risk | Medium | The company has sunk over US$10 million into an export-oriented model; failure to quickly secure foreign regulatory approvals or distribution partnerships would strand this capacity in a small domestic market. |
| Competitive Risk | Medium | While local competition is currently thin, well-funded producers in Colombia and Canada are already targeting Latin American patients and could undercut Pharma Industries on price or brand recognition before it establishes export volumes. |
| Regulatory Risk | High | Paraguay’s domestic medicinal cannabis framework is still evolving; any tightening of cultivation or export rules, or delays in mutual recognition of GMP standards by target countries, could directly block the international revenue stream the entire US$10 million investment is built upon. |
| Reputation Risk | Low | As a pharmaceutical-grade operation with vertical integration and GMP alignment, reputational risk is moderate only if product quality ever deviates—no known incidents exist, but any contamination or labelling failure in a highly scrutinised cannabis market could erode trust rapidly. |
| Technology Disruption | Low | The indoor, pharmaceutical-grade model is state-of-the-art for this segment; disruption would require a new extraction or formulation technology that significantly lowers cost or improves bioavailability, but no such breakthrough appears imminent in the medicinal cannabis niche. |
| Commercial Opportunity | High | Paraguay’s lower operational costs and early regulatory consolidation could allow Pharma Industries to become a low-cost, high-quality exporter to underserved markets in Brazil, Argentina, and potentially Europe, capturing first-mover advantages if it secures export approvals quickly. |
Comments 0